Overview

A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is assessment of efficacy and safety of OligoG as a dry powder formulation, in adult subjects with cystic fibrosis.
Phase:
Phase 2
Details
Lead Sponsor:
AlgiPharma AS
Collaborators:
Eurostars
Smerud Medical Research International AS
Treatments:
Alginic acid